S&P 500   3,324.29 (+0.23%)
DOW   29,316.67 (+0.06%)
QQQ   222.70 (+0.19%)
AAPL   316.34 (+0.35%)
MSFT   166.18 (+0.01%)
GOOGL   1,465.18 (+1.04%)
AMZN   1,864.47 (-0.72%)
CGC   25.03 (+3.00%)
NVDA   248.10 (-0.33%)
BABA   226.43 (+1.11%)
GE   11.80 (-0.34%)
AMD   50.92 (+2.29%)
T   38.36 (+0.87%)
PRI   128.79 (+0.33%)
BAC   34.63 (-0.26%)
GILD   63.12 (-0.13%)
DIS   144.71 (-0.28%)
S&P 500   3,324.29 (+0.23%)
DOW   29,316.67 (+0.06%)
QQQ   222.70 (+0.19%)
AAPL   316.34 (+0.35%)
MSFT   166.18 (+0.01%)
GOOGL   1,465.18 (+1.04%)
AMZN   1,864.47 (-0.72%)
CGC   25.03 (+3.00%)
NVDA   248.10 (-0.33%)
BABA   226.43 (+1.11%)
GE   11.80 (-0.34%)
AMD   50.92 (+2.29%)
T   38.36 (+0.87%)
PRI   128.79 (+0.33%)
BAC   34.63 (-0.26%)
GILD   63.12 (-0.13%)
DIS   144.71 (-0.28%)
S&P 500   3,324.29 (+0.23%)
DOW   29,316.67 (+0.06%)
QQQ   222.70 (+0.19%)
AAPL   316.34 (+0.35%)
MSFT   166.18 (+0.01%)
GOOGL   1,465.18 (+1.04%)
AMZN   1,864.47 (-0.72%)
CGC   25.03 (+3.00%)
NVDA   248.10 (-0.33%)
BABA   226.43 (+1.11%)
GE   11.80 (-0.34%)
AMD   50.92 (+2.29%)
T   38.36 (+0.87%)
PRI   128.79 (+0.33%)
BAC   34.63 (-0.26%)
GILD   63.12 (-0.13%)
DIS   144.71 (-0.28%)
S&P 500   3,324.29 (+0.23%)
DOW   29,316.67 (+0.06%)
QQQ   222.70 (+0.19%)
AAPL   316.34 (+0.35%)
MSFT   166.18 (+0.01%)
GOOGL   1,465.18 (+1.04%)
AMZN   1,864.47 (-0.72%)
CGC   25.03 (+3.00%)
NVDA   248.10 (-0.33%)
BABA   226.43 (+1.11%)
GE   11.80 (-0.34%)
AMD   50.92 (+2.29%)
T   38.36 (+0.87%)
PRI   128.79 (+0.33%)
BAC   34.63 (-0.26%)
GILD   63.12 (-0.13%)
DIS   144.71 (-0.28%)
Log in

NASDAQ:IFRX - Inflarx Stock Price, Forecast & News

$3.60
-0.12 (-3.23 %)
(As of 01/17/2020 01:50 PM ET)
Today's Range
$3.49
Now: $3.60
$3.83
50-Day Range
$3.16
MA: $3.74
$4.54
52-Week Range
$2.17
Now: $3.60
$53.10
Volume10,814 shs
Average Volume382,791 shs
Market Capitalization$93.47 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.16
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IFRX
CUSIPN/A
CIKN/A
Phone49-36-4150-8180

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$7.64 per share

Profitability

Net Income$-35,210,000.00

Miscellaneous

Employees36
Market Cap$93.47 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive IFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.


Revealed... The Top 3 Stocks for 2020 (Ad)


Investors looking for the best way to potentially double their money in 2020 -- regardless of whether the overall markets are up or down -- should look no further than these 3 unique stocks.

This Special Report reveals the names of these stocks and provides everything you need to invest right away.

Inflarx (NASDAQ:IFRX) Frequently Asked Questions

What is Inflarx's stock symbol?

Inflarx trades on the NASDAQ under the ticker symbol "IFRX."

How were Inflarx's earnings last quarter?

Inflarx NV (NASDAQ:IFRX) announced its earnings results on Thursday, November, 7th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $0.04. View Inflarx's Earnings History.

When is Inflarx's next earnings date?

Inflarx is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Inflarx.

What price target have analysts set for IFRX?

9 Wall Street analysts have issued 12 month price targets for Inflarx's stock. Their forecasts range from $5.00 to $44.00. On average, they anticipate Inflarx's share price to reach $12.50 in the next year. This suggests a possible upside of 247.2% from the stock's current price. View Analyst Price Targets for Inflarx.

What is the consensus analysts' recommendation for Inflarx?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inflarx in the last year. There are currently 2 sell ratings and 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inflarx.

Has Inflarx been receiving favorable news coverage?

Media stories about IFRX stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Inflarx earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Inflarx.

Are investors shorting Inflarx?

Inflarx saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 1,040,000 shares, a decrease of 8.8% from the December 15th total of 1,140,000 shares. Based on an average daily volume of 675,400 shares, the days-to-cover ratio is currently 1.5 days. Approximately 5.8% of the company's shares are short sold. View Inflarx's Current Options Chain.

Who are some of Inflarx's key competitors?

What other stocks do shareholders of Inflarx own?

Who are Inflarx's key executives?

Inflarx's management team includes the folowing people:
  • Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 47)
  • Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 49)
  • Mr. Arnd Christ, Chief Financial Officer (Age 53)
  • Mr. Jason M. Marks J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 43)
  • Mr. Jordan Silverstein, Head of Corp. Devel. & Strategy

When did Inflarx IPO?

(IFRX) raised $100 million in an initial public offering (IPO) on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

How do I buy shares of Inflarx?

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Inflarx's stock price today?

One share of IFRX stock can currently be purchased for approximately $3.60.

How big of a company is Inflarx?

Inflarx has a market capitalization of $93.47 million. The company earns $-35,210,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Inflarx employs 36 workers across the globe.View Additional Information About Inflarx.

What is Inflarx's official website?

The official website for Inflarx is http://www.inflarx.de/.

How can I contact Inflarx?

Inflarx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180.


MarketBeat Community Rating for Inflarx (NASDAQ IFRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  373
MarketBeat's community ratings are surveys of what our community members think about Inflarx and other stocks. Vote "Outperform" if you believe IFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel